Overview

Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy

Status:
Unknown status

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

The objective of the study is to assess the safety and ability of vorinostat, a drug currently licensed for the treatment of a type of lymphoma, to 'turn on' dormant HIV infected CD4 T-cells.

Phase:

Phase 2

Details

Lead Sponsor:

Bayside Health

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Vorinostat